Key result
Losartan decreased the risk of ESRD by 24.6%, 26.3%, and 35.3% in the highest, middle, and lowest tertiles of baseline serum creatinine, respectively, compared to conventional treatment.
Why the study?
Does losartan reduce the incidence of ESRD and heart failure hospitalizations in individuals with type 2 diabetes and overt nephropathy across different stages of renal function?
RCT (n=1,513)
Does losartan reduce the incidence of ESRD and heart failure hospitalizations in individuals with type 2 diabetes and overt nephropathy across different stages of renal function?
Effect estimate: RRR 24.6% to 35.3%
Losartan provides renoprotection and reduces heart failure hospitalizations in patients with type 2 diabetes and overt nephropathy, even at advanced stages of chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Losartan may reduce ESRD risk even in advanced CKD; supports extending RAS inhibitor use but remains hypothesis-generating pending RCTs.
Remuzzi et al. (2004) conducted an RCT in Type 2 diabetes and overt nephropathy (n=1,513). Losartan vs. Placebo / conventional treatment was evaluated on Incidence of ESRD (RRR 24.6% to 35.3%). Losartan decreased the risk of ESRD by 24.6%, 26.3%, and 35.3% in the highest, middle, and lowest tertiles of baseline serum creatinine, respectively, compared to conventional treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: